Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum P9 (also known as Lactiplantibacillus plantarum P9) is a specific probiotic bacterial strain used as a dietary supplement for gastrointestinal health. It is administered orally and has been evaluated in randomized, double-blind, placebo-controlled clinical trials for its effects on chronic diarrhea and chronic constipation in adults. The mechanism of action involves modulation of the gut microbiome and metabolome—P9 increases beneficial bacteria such as Ruminococcus_B gnavus while reducing potentially harmful taxa like Oscillospiraceae sp., Lachnospiraceae sp., and Herelleviridae. It also enhances the production of bioactive metabolites involved in amino acid and fatty acid metabolism while decreasing metabolites associated with impaired intestinal barrier function (e.g., p-cresol, methylamine). Clinical studies have shown that supplementation with L. plantarum P9 can modestly but significantly reduce diarrhea severity scores in young adults with chronic diarrhea[1][6][8], improve bowel movement frequency in patients with chronic constipation[2], and positively impact quality-of-life measures related to gastrointestinal symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus plantarum P9.